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Background: Severe hypoxemia is a major complication of chronic obstructive pulmonary
disease (COPD). Long-term oxygen therapy is beneficial in hypoxemic COPD patients. However,
the clinical and radiographic predictors of hypoxemia and the use of oxygen therapy are not
well described. This study aimed to find the correlates of resting hypoxemia and the pattern
of oxygen use in moderate to severe COPD patients.
Methods: Subjects with GOLD stage II or higher COPD from the first 2500 COPDGene subjects
were included in this analysis. All subjects were current or ex-smokers between ages 45 and
80. Severe resting hypoxemia was defined as room air oxygen saturation (SpO2) 88%. Use
of supplemental oxygen therapy was determined by questionnaire.
Results: Eighty-two of 1060 COPD subjects (7.7%) had severe resting hypoxemia. Twenty-one of
the 82 (25.6%) were not using continuous supplemental oxygen. Female sex, higher BMI, lower
FEV1, and enrollment in Denver were independent risk factors for hypoxemia; emphysema
severity on quantitative chest CT scan did not predict hypoxemia. 132 of 971(13.6%)
subjects without severe resting hypoxemia were using continuous supplemental oxygen.tional Institutes of Health grants U01HL089856 (E.K.S.), U01HL089897 (J.D.C.), K08HL080242 (C.P.H.),
m the Alpha-1 Foundation (C.P.H.).
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ing.harvard.edu (C.P. Hersh).
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1212 D.K. Kim et al.In non-hypoxemic oxygen users, Denver recruitment, higher BMI, lower FEV1, and more severe
dyspnea were associated with the use of continuous oxygen.
Conclusions: A large number of COPD patients without severe hypoxemia were using supple-
mental oxygen therapy and the pattern of oxygen use was affected by factors other than
resting SpO2 and emphysema severity. Longitudinal data will be required to reveal the effects
of oxygen therapy in this subgroup.
Clinical trial registration: http://clinicaltrials.gov (NCT00608764).
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Hypoxemia in chronic obstructive pulmonary disease (COPD)
results from physiologic derangements such as airflow limi-
tation, ventilationeperfusion imbalance, loss of lung paren-
chyma, and remodeling and destruction of the pulmonary
vasculature. Lung function, specifically the forced expiratory
volume in 1 s (FEV1), is correlatedwith arterial oxygenation in
COPD.1 Nevertheless, some patients suffer from hypoxemia
with relatively preserved lung function while other patients
maintain normal oxygen levels despite advanced COPD. This
suggests that there are other factors which contribute to
hypoxemia, besides impaired lung mechanics.
Chronic hypoxemia is a strong predictor of mortality in
COPD.2,3 Long-term oxygen treatment (LTOT) is known to
improve survival in COPD patients with severe resting
hypoxemia.4,5 Although the criteria for LTOT prescription are
well-established, thereare fewreports on theactual patterns
of LTOTusage, including the factors which affect the pattern
of LTOT use in hypoxemic COPD patients, and the use of
supplemental oxygen therapy in non-hypoxemic COPD
patients. Therefore, we sought to identify the determinants
besides hypoxemia that may affect the actual pattern of
oxygen use in COPD, including emphysema severity, exercise
capacity, and quality of life, in a large cohort of moderate to
very severe COPD patients enrolled in the COPDGene Study.
Materials and methods
Study subjects
The Genetic epidemiology of COPD (COPDGene) Study is
a multicenter observational study, recruiting COPD cases and
smoking controls, who were non-Hispanic whites and Afri-
caneAmericans ages 45 to 80 with at least 10 pack-years of
smoking history. Study procedures have been described
elsewhere.6 Among the first 2500 subjects (April 2010
COPDGene data set) recruited at 18 clinical centers including
Denver (altitude 5280 ft.), COPD subjects in GOLD Stage II or
greater (post-bronchodilator FEV1<80% predictedwith FEV1/
FVC<0.7) were included in this analysis. Informed consent
was obtained from all subjects, and the study was approved
by institutional review boards at all participating centers
(Partners Healthcare IRB, # 2007P000554).
Study procedures
Spirometry was performed before and after inhalation of 2
puffs of albuterol according to American Thoracic Society(ATS) criteria.7 Questionnaires included a modified version
of the ATS Respiratory Epidemiology Questionnaire, demo-
graphic information, medications, medical history, and the
St George’s Respiratory Questionnaire (SGRQ).8 The time of
usage and average daily duration of supplemental oxygen
therapy were determined by questionnaire.
Oxygen saturation by pulse oximeter (SpO2) was recor-
ded after the subject had remained at rest in the seated
position for at least 5 min. The pulse oximeter was placed
on a finger without nail polish and the reading was
considered valid only if a strong pulse was demonstrable.
The median value was obtained while observing the
monitor over a 1-min period. In subjects using supplemental
oxygen, the subject’s oxygen was discontinued while
monitoring the oximeter for a period of 5 min.9 The
apparent median value obtained while observing the
monitor over a 1-min observation period was recorded. If
the pulse oximeter reading fell to 82% or less, oxygen was
replaced and a reading of 82% was recorded as the subject’s
SpO2.
CT imaging
Each subject underwent an inspiratory chest CT with
a radiation dose of 200 mAs and an expiratory chest CT at
50 mAs. Percent of emphysema (% of lung <950 HU) on the
inspiratory CT scan, and gas trapping (% of lung <856 HU)
on the expiratory CT scan were calculated using 3D-SLICER
software (http://www.slicer.org).10,11 Total lung capacity
(TLC) was also determined using 3D-SLICER software. Pre-
dicted value for TLC was computed from the equations of
Crapo et al.12 Airway wall area was estimated as the square
root of airway wall area for a hypothetical 10 mm luminal
perimeter (Pi10) airway using VIDA software.
13,14 For this
paper, CT images of hypoxemic cases with GOLD stage II
COPD were reviewed independently by a chest radiologist
(FLJ) and a pulmonologist (DKK) using the COPDGene CT
assessment form (http://www.copdgene.org/). Discrep-
ancies were resolved by discussion.
Statistical analysis
Severe resting hypoxemia was defined by SpO2 88%.
‘Continuous’ oxygen therapy was defined when a patient
stated that he/she used oxygen at rest, with activity and
during sleep. ‘Intermittent’ oxygen therapy was defined
when a subject was using oxygen only during exercise and/
or sleep.
Univariate analyses used the chi-square test or Fisher’s
exact test for categorical variables and the student t-test
Hypoxemia and oxygen therapy in COPDGene 1213for continuous variables. CochraneArmitage trend test was
used for categorical variables. Logistic regression was
applied for analyses of binary outcomes, while linear
regression analysis was applied for resting SpO2 as a quan-
titative outcome. Statistical analysis used SAS (version 9.1)
and statistical significance was determined by p < 0.05.
Results
Characteristics of hypoxemic and non-hypoxemic
COPD patients
One thousand and sixty-one COPD cases were included in
the analysis (Table 1); 1053 cases had complete question-
naire data on oxygen use. Eighty-two of 1060 COPD cases
with GOLD stage II or higher (7.70%) showed severe resting
hypoxemia, with mean SpO2 85.1  2.5%. The mean SpO2 of
the 978 non-hypoxemic patients was 95.2  2.4%. The
proportion of hypoxemic cases increased with higher GOLD
stage, (2.8% in stage II, 9.1% in stage III, and 19.2% in stage
IV, p < 0.0001 for trend).
Compared with cases enrolled at lower altitude centers,
patients recruited in Denver showed lower resting SpO2,
more severe airflow obstruction and higher severity of
emphysema (Supplementary Table 1). In multivariate
analysis, recruitment in Denver was associated with lower
FEV1 (%predicted) and higher TLC as well as lower oxygen
saturation. Enrollment in Denver was not associated with 6-
min walk distance, SGRQ score and severity of emphysema
and gas trapping on volumetric chest CT (Supplementary
Table 2).
The patients recruited in Denver comprised the majority
of the hypoxemic group (84.2%) and their mean saturation
was 90.5  4.3%, which was significantly lower thanTable 1 Characteristics of the COPD cases classified by the pre
Variable Hypoxemic
Age, years 66.1  8.7
Male gender, n (%) 33 (40.2)
BMI, kg m2 28.3  7.4
White race, n (%) 73 (89.0)
School completed, high school or less, n (%) 27 (32.9)
Current smokers, n (%) 12 (14.6)
Lifetime smoking intensity, Pack-years 53.2  24.
Enrollment in Denver, n (%) 69 (84.2)
MMRC dyspnea scale 3, n (%) 59 (72.0)
6-min walk distance, ft 872  382
St. George’s Respiratory Questionnaire score 46.2  18.
GOLD II/III/IV, % 18.3/37.8/
FEV1/FVC 0.40  0.1
FEV1, % predicted 34.9  15.
FVC, % predicted 65.8  19.
Resting SpO2, % 85.1  2.5
CT emphysema, % of total lung 21.1  13.
CT gas trapping, % of total lungb 48.9  18.
TLC by CT, % predicted 102.4  14
a Data listed as number (%) for frequency or mean  standard devia
b 64 subjects missing expiratory CT analysis.95.6  2.5% in the non-Denver cases (p < 0.0001). Women
were more common and current smokers were less common
among the hypoxemic patients, including those in Denver.
Hypoxemic patients showed more severe airflow obstruc-
tion and greater limitation in exercise capacity. On quan-
titative chest CT scan analysis, the extent of emphysema
and gas trapping were higher in the hypoxemic group.
Predictors of severe resting hypoxemia in COPD
patients
Because of the large proportion of hypoxemic cases
enrolled in Denver, the multivariate analyses were done
after stratifying the population by study center (Table 2). In
a logistic regression model, female gender, higher BMI, and
decreasing FEV1 were independent risk factors for hypox-
emia in all subjects; age was significant only in Denver
subjects. In the quantitative analysis of SpO2, age, BMI, and
FEV1 were significant predictors in Denver subjects and all
subjects. BMI was positively correlated with FEV1 (rZ 0.17,
p < 0.0001) and negatively with percent of emphysema
(r Z 0.37, p < 0.0001), yet higher BMI rather than lower
BMI was a predictor of severe resting hypoxemia. The
plausible explanation is that the characteristics of our study
population may be different from those of previous reports
which focused on COPD subjects with low BMI.15e17 The
mean value of BMI in this population was 28.0  6.2 kg/m2,
which was higher than in other studies.15e17 In addition, an
increased prevalence of obesity or overweight (BMI 28 kg/
m2) has also been reported in patients with chronic bron-
chitis.18,19 Although only a limited proportion of subjects
(848/1060 cases, 80.0%) were evaluated for the airway wall
thickness (Pi10) on chest CT, we found that the mean value
was increased in subjects with high BMI compared to
subjects with lower BMI (3.78  0.11 vs. 3.82  0.14,sence of severe resting hypoxemia (SpO2 88%).a
n Z 82 Non-hypoxemic n Z 978 p
64.0  8.4 0.03
515 (52.7) 0.03
27.9  6.1 0.64
789 (80.7) 0.06
401 (41.0) 0.15
334 (34.2) 0.0003
5 53.2  26.9 1.0
159 (16.3) <0.0001
486 (49.7) 0.0001
1158  426 <0.0001
2 39.5  21.1 0.006
43.9 52.9/31.6/15.5 <0.0001
1 0.49  0.13 <0.0001
4 50.1  17.9 <0.0001
4 77.2  17.3 <0.0001
95.2  2.4 <0.0001
8 15.0  13.1 <0.0001
2 41.7  20.4 0.003
.5 99.8  17.3 0.13
tion for quantitative variables.
Table 2 Logistic regression analysis for the risk of severe resting hypoxemia and linear regression analysis for resting SpO2 as
a quantitative outcome.a
Population Presence of hypoxemia Resting oxygen saturation
Total population
including cases enrolled
in Denver (n Z 1060)
Cases enrolled in
Denver only
(n Z 228)
Total population
including cases
enrolled in Denver
Cases enrolled in
Denver only
Variable OR P OR P b P b P
Age, year 1.03 0.11 1.08 0.004 0.03 0.03 0.09 0.003
Gender, female 2.03 0.004 4.15 0.0002 0.20 0.32 1.25 0.009
Race, white 1.59 0.22 0.31 0.20 1.52 <0.0001 0.01 0.99
BMI, kg/m2 1.05 0.04 1.11 0.003 0.07 0.0001 0.17 <0.0001
FEV1, % predicted 0.94 <0.0001 0.93 <0.0001 0.06 <0.0001 0.12 <0.0001
Current smoking 0.64 0.21 1.10 0.86 0.29 0.27 0.11 0.86
CT emphysema, %
(950HU)
1.0 0.65 1.02 0.22 0.01 0.28 0.03 0.28
a Models were adjusted for age, gender, race, BMI, current smoking status, FEV1 % predicted, and percent of emphysema on chest CT
scan.
1214 D.K. Kim et al.p < 0.0001). This may suggest that subjects with higher BMI
contained patients with airway disease but more mild
emphysema, and it also reflects the minor contribution
of emphysema severity to the development of resting
hypoxemia in overweight or obese COPD patients.
Fifteen cases with GOLD II COPD (mean FEV1% predicted
60.8 8.6%) were found to have resting hypoxemia; 11 cases
were recruited in Denver. On quantitative CT scan analysis,
10 cases showed significant extent of emphysema (range
10.7%e34.7%) and another 3 cases showed severe gas trap-
ping (range 20.9e36.2%) despite no evidence of prominent
emphysema. Two cases had no significant abnormality on
review of chest CT scan by two independent readers, but
they were obese with BMIs of 36.1 and 36.3 kg/m2. There
was no evidence of clinically significant interstitial lung
disease or enlargement of cardiac size on these 15 chest CTs
(Supplementary Table 3). The extent of emphysema by
computerized analysis was higher in these 15 cases than in
513 non-hypoxemic cases with GOLD stage II COPD
(13.5  8.8% vs. 8.7  8.2%, p Z 0.03).
In linear regression analysis for resting SpO2, age, white
race, higher BMI, and lower FEV1 were independent risk
factors for decreasing SpO2 in all subjects (Table 2). Race
was not significant in Denver subjects, but female gender
was significant. In both multiple regression models, CT
emphysema severity was not a significant predictor of
hypoxemia or lower resting oxygen saturation. Emphysema
severity did not improve the prediction of hypoxemia over
FEV1 alone.
Use of supplemental oxygen in COPD patients
Twenty-one of 82 patients with severe resting hypoxemia
(25.6%) at the time of the study visit were not using
continuous oxygen; 13 subjects reported using oxygen
during exercise and/or sleep, and 8 did not report any use
of oxygen therapy.
Surprisingly, 132 of 971 patients without severe resting
hypoxemia (13.6%) were using continuous oxygen therapy.
An additional 122 cases without severe resting hypoxemia
(12.6%) were using oxygen only during exercise and/orsleep. The majority of subjects using oxygen therapy
without severe resting hypoxemia had oxygen saturations
that were clearly in the non-hypoxemic range (Fig. 2).
However, the proportion of non-hypoxemic cases using
oxygen therapy increased with increasing GOLD stage
(Fig. 1).
Compared with hypoxemic subjects not using continuous
oxygen, hypoxemic subjects using oxygen continuously at
rest had lower SpO2 (Fig. 3) and were more commonly men
(Table 3). Patients enrolled in Denver comprised most of
hypoxemic subjects using continuous supplemental oxygen.
There was no difference in age, race, BMI, level of educa-
tion, and pack-years of smoking between hypoxemic COPD
subjects who were or were not using continuous oxygen.
Among the non-hypoxemic subjects, subjects using
continuous oxygen had lower SpO2 than subjects who were
not using supplemental oxygen (Fig. 3). There was no
difference in SpO2 between intermittent and continuous
oxygen users without resting hypoxemia. The group using
oxygen continuously was older and included more cases
recruited from Denver and more ex-smokers compared with
non-hypoxemic COPD cases not using oxygen.
In both the hypoxemic and non-hypoxemic groups,
subjects using oxygen continuously showed more severe
symptoms, including a higher MMRC dyspnea scale, shorter
6MWD, and higher SGRQ score, and more severe airflow
obstruction (Table 4).Predictors of continuous oxygen use in hypoxemic
COPD patients
In multivariate analysis (Table 5), enrollment in Denver and
severe dyspnea were independent predictors for continuous
use of oxygen in hypoxemic COPD patients. Women were
less likely to use continuous oxygen. The severity of airflow
obstruction was not an independent risk factor for contin-
uous oxygen use. Neither extent of emphysema nor gas
trapping on chest CT predicted continuous use of oxygen in
hypoxemic COPD patients. In a model with the same
covariates, replacing SGRQ score or 6MWD for MMRC
Figure 1 The proportion of cases using oxygen therapy (continuously or intermittently) according to the presence of severe
hypoxemia (SpO2 88%) and the severity of COPD (GOLD stage).
Hypoxemia and oxygen therapy in COPDGene 1215dyspnea scale, higher SGRQ score and shorter 6MWD were
independent predictors for the continuous use of oxygen
(Supplementary Table 4).Predictors of oxygen use in non-hypoxemic COPD
patients
Comparing the non-hypoxemic COPD patients who used
oxygen continuously vs. intermittently, higher BMI and
lower FEV1 as well as more severe dyspnea were significant
predictors for the continuous use of oxygen (Table 5).Figure 2 The distribution of room air oxygen saturation among CO
supplemental oxygen.Subjects with lower level of education showed a trend of
increasing continuous oxygen use. COPD subjects with
lower level of education had a greater smoking history
(58.8  25.3 vs. 51.2  23.7 pack-years, p Z 0.02), lower
lung function (FEV1 33.1  14.4% vs. 38.0  16.6, pZ 0.02),
and shorter 6MWD (833  395 feet vs. 986  387 pZ 0.003)
compared to the subjects with higher level of education,
leading to a higher rate of oxygen use. Shorter 6MWD
was a significant predictor for continuous oxygen use in
this group, while higher SGRQ score showed a trend
toward increasing continuous oxygen use (Supplementary
Table 4).PD subjects without severe resting hypoxemia who were using
Figure 3 Resting oxygen saturation according to the groups defined by hypoxemia and oxygen use. Group 1: Hypoxemic COPD
subjects using continuous supplemental oxygen therapy; Group 2: Hypoxemic COPD subjects using supplemental oxygen therapy
with exercise and/or sleep only or not using supplemental oxygen therapy; Group 3: Non-hypoxemic COPD subjects using
continuous supplemental oxygen therapy; Group 4: Non-hypoxemic COPD subjects using supplemental oxygen therapy with
exercise and/or sleep only; Group 5: Non-hypoxemic COPD subjects not using supplemental oxygen therapy.
1216 D.K. Kim et al.Comparing non-hypoxemic COPD patients who were and
were not using supplemental oxygen, decreasing SpO2,
older age, female gender, AfricaneAmerican race, enroll-
ment from Denver, higher BMI, ex-smoker status, lower
FEV1, greater CT emphysema, and severe dyspnea were
significant predictors of oxygen use (Table 5). Higher SGRQ
score and shorter 6MWD were also predictors for using
oxygen in this group (Supplementary Table 4).Discussion
In a large study of COPD subjects representing a range of
disease severity, we found that female gender, high altitude,
and decreased lung function contributed to the presence of
severe hypoxemia, while emphysema did not affect severe
resting hypoxemia. Both overuse and underuse of LTOTwere
common. More than 25% of severely hypoxemic COPD
patients were not using continuous oxygen, while 13.5% of
moderate to very severe COPD cases without severe resting
hypoxemia reported continuous oxygen use. Both dyspnea
and exercise capacity were significant predictors for
continuous oxygen use, whereas resting SpO2 and CT
emphysema severity did not predict oxygen use.
Subjects enrolled in Denver, Colorado comprised the
majority of those with severe resting hypoxemia. Colorado
has one of the highest COPD mortality rates in the U.S., and
high altitude has been suggested as a possible cause.20,21 The
resting oxygen saturation in cases enrolled in Denver wassignificantly lower than that of the cases in other centers
even after adjusting for other COPD severity measures,
which reflects the effect of high altitude on oxygen satura-
tion. In addition to altitude, female gender, higher BMI and
lower FEV1 were risk factors for severe resting hypoxemia
while the severity of emphysema on CT does not predict
resting hypoxemia or lower oxygen saturation. Emphysema
has been reported a pathologic process resulting in
decreasing diffusing capacity in COPD22 and arterial desa-
turation during exercise.23,24 However, radiographic severity
of emphysema was not a risk factor for resting hypoxemia in
this study group. It suggests that simple emphysema severity
on chest CT may not be a good indicator in assessing hypox-
emic status of COPD patients at rest, which results from
complicated physiologic derangements including airflow
limitation, ventilationeperfusion imbalance, loss of lung
parenchyma, and remodeling and destruction of the pulmo-
nary vasculature. Measurement of diffusing capacity may
help address these issues, but diffusing capacity measure-
ments were not available in COPDGene.
Surprisingly, 15 cases with GOLD stage II COPD were
found to have severe resting hypoxemia. However, majority
(86.7%) showed definite emphysema and/or gas trapping on
chest CT. Eleven of 15 cases were recruited from Denver.
Therefore, the combined effects of high altitude and
severe emphysema or gas trapping may yield hypoxemia
despite relatively preserved lung function, although
emphysema was not a risk factor for severe resting
hypoxemia in the total population.
Table 3 Characteristics of subjects classified by the presence of severe hypoxemia (SpO2 88%) and the use of supplemental
oxygen therapy.a
Groups Hypoxemic COPD (n Z 82) Non-hypoxemic COPD (n Z 971)
Group 1
(n Z 61)
Group 2
(n Z 21)
P Group 3
(n Z 132)
Group 4
(n Z 122)
Group 5
(n Z 717)
P(3 vs. 4)b P(3 vs.5)c
Variables Continuous
oxygen use
Intermittent or
no oxygen use
Continuous
oxygen use
Intermittent
oxygen use
No oxygen
use
Resting SpO2 84.7  2.6 86.2  2.2 0.02 94.1  2.7 93.8  2.4 95.7  2.1 0.34 <0.0001
O2 h/day 23.4  1.7 9.4  4.5 <0.0001 21.6  5.2 7.9  4.6 e <0.0001 e
Age, years 65.4  9.0 68.2  7.7 0.21 66.0  7.9 67.3  7.3 63.1  8.4 0.16 0.0003
Male, n (%) 29 (47.5) 4 (19.1) 0.04 61 (46.2) 56 (45.9) 395 (55.1) 0.96 0.06
BMI, kg m2 28.9  7.7 26.7  6.2 0.25 27.9  6.6 27.1  5.2 28.1  6.1 0.28 0.71
White Race, % 56 (91.8) 17 (81.0) 0.22 104 (78.8) 108 (88.5) 571 (79.6) 0.04 0.82
Enrollment
in Denver, %
55 (90.2) 14 (66.7) 0.02 42 (31.8) 42 (34.4) 75 (10.5) 0.66 <0.0001
School completed
(high school or less)
20 (32.8) 7 (33.3) 0.96 60 (45.5) 35 (28.7) 301 (42.0) 0.006 0.46
Current smoker, n (%) 6 (9.8) 6 (28.6) 0.07 15 (11.4) 19 (15.6) 300 (41.8) 0.32 <0.0001
Lifetime smoking
intensity, pack-years
54.9  24.8 48.3  23.6 0.29 56.3  26.1 51.6  22.6 52.9  27.7 0.13 0.20
a Data listed as number (%) for frequency or mean  standard deviation for quantitative variables. There were seven subjects with
missing data regarding oxygen therapy in the non-hypoxemic group.
b p-value of the comparison between groups 3 and group 4.
c p-value of the comparison between group 3 and group 5.
Hypoxemia and oxygen therapy in COPDGene 1217Although COPDGene is not a population-based sample,
LTOTuse in COPDGene subjects may reflect the actual usage
of supplemental oxygen therapy in COPD patients in the U.S.
In patients without severe resting hypoxemia, more than
a quarter were using supplemental oxygen, and over half of
these subjects were using it more than 20 h per day. The
National Emphysema Treatment Trial (NETT) found that
more than a third of severe COPD patients without severe
resting hypoxemia were using supplemental oxygen,25 and
our report extends this finding to subjects with a broader
range of COPD severity. Non-hypoxemic subjects may be
prescribed for LTOT for hypoxemia at the time of hospital
discharge following an acute exacerbation. Some of these
patients may have continued to use oxygen after recovery
fromtheacuteexacerbation, despite improvement in resting
oxygen saturation. There are reports that only 35e65% of
patients prescribed LTOT for an acute exacerbation may be
reassessed for theneed for LTOTin stable condition.26 Among
non-hypoxemic subjects, cases with a history of an ER visit or
hospitalization during the past year were more likely to be
using oxygen continuously.
Exercise intolerance was a predictor of oxygen use in
COPD cases. Oxygen supplementation during exercise has
been reported to improve exercise tolerance in COPD
patients who are not hypoxemic at rest.27,28 We could not
address this indication in our study, since exercise oximetry
data were not collected in COPDGene. Considering the
frequency of oxygen use in non-hypoxemic COPD patients,
a risk-benefit analysis of the use of oxygen in normoxemic
COPD patients should be performed, given the finding in
NETT that non-hypoxemic subjects receiving continuous
supplemental oxygen had increased mortality.25
Our study found distinct determinants of continuous
oxygen use in hypoxemic and non-hypoxemic COPDpatients. Even though the indication for LTOT is the pres-
ence of severe hypoxemia, resting oxygen saturation was
not a determinant of oxygen use when hypoxemic and non-
hypoxemic subjects were considered separately. We also
found that traditional indicators for the severity of COPD
such as FEV1, BMI and quantitative CT emphysema were
determinants of continuous oxygen use in non-hypoxemic
subjects, but not in hypoxemic COPD cases. Instead, severe
dyspnea was more strongly related to LTOT use among
hypoxemic patients. Hypoxemic subjects using continuous
oxygen showed higher TLC than those of subjects using
oxygen inadequately. Hyperinflation may influence func-
tional impairment more than reduced FEV1 or emphysema
severity in this group.
Despite these findings, this study has several limita-
tions. Although COPDGene is the one of the largest studies
of COPD patients in the U.S., the relatively small number of
hypoxemic cases may reduce the power to identify rele-
vant predictors for hypoxemia. Arterial blood gas
measurements were not available in COPDGene, though
oxygen saturation is generally an accurate indicator of
hypoxemia and is the more common test for oxygen
prescription in the U.S. Also, the COPDGene study did not
collect information on medical insurance status, which
might affect patterns of oxygen prescription and use.
Although we collected information about actual oxygen
use, actual oxygen prescriptions were not determined.
Therefore, we could not assess adherence to prescribed
oxygen. Without oximetry measurements during exercise
or sleep, we were unable to assess whether the use of
oxygen during exercise and sleep by patients without
resting hypoxemia was appropriate.
In the COPDGene Study, we found that high altitude,
female gender and higher BMI predicted severe resting
Table 4 Respiratory symptoms, spirometry, and radiographic characteristics of subpopulations classified by the presence of severe hypoxemia (SpO2 88%) and the pattern of
supplemental oxygen therapy.a
Groups Hypoxemic COPD (n Z 82) Non-hypoxemic COPD (n Z 971)
Group 1 (n Z 61) Group 2 (n Z 21) P Group3 (n Z 132) Group 4 (n Z 122) Group 5 (n Z 717) P(3 vs. 4)b P(3 vs.5)c
Variables Continuous
oxygen use
Intermittent or
no oxygen use
Continuous
oxygen use
intermittent
oxygen use
No oxygen use
Symptoms
MMRC dyspnea scale (3), n(%) 50 (82.0) 9 (42.9) 0.0006 108 (81.8) 79 (64.8) 294 (41.0) 0.002 <0.0001
6-min walk distance, ft 816  381 1034  347 0.02 810  382 1058  371 1244  404 <0.0001 <0.0001
St. George’s Respiratory
Questionnaire score
50.3  17.0 34.2  16.3 0.0003 52.9  16.7 45.7  16.7 35.9  21.2 0.0006 <0.0001
Severe exacerbation in
past year, n(%)
21 (34.4) 8 (38.1) 0.76 42 (31.8) 33 (27.1) 122 (17.0) 0.41 <0.0001
Spirometry and radiographic findings
GOLD II/III/IV, % 14.8/34.4/50.8 28.6/47.6/23.8 0.08 18.9/28.0/53.0 29.5/39.3/31.2 63.6/30.7/5.7 0.002 <0.0001
FEV1/FVC 0.38  0.11 0.43  0.10 0.10 0.38  0.12 0.42  0.12 0.52  0.12 0.009 <0.0001
FEV1 % predicted 32.9  15.4 40.7  14.1 0.05 32.7  16.0 39.8  15.1 55.3  15.7 0.0003 <0.0001
FVC % predicted 63.6  18.6 72.3  20.7 0.08 63.3  18.4 70.3  15.8 81.1  15.6 0.001 <0.0001
CT emphysema, % of total lung 21.8  13.1 19.2  15.7 0.47 24.9  14.0 21.6  14.5 11.9  11.0 0.07 <0.0001
CT gas trapping, % of total lungd 50.5  16.8 44.0  21.5 0.17 55.2  18.0 51.4  19.0 37.3  19.3 0.11 <0.0001
TLC by chest CT, % predicted 103.2  13.9 99.9  16.0 0.37 104.3  17.6 102.8  17.6 98.3  17.0 0.50 0.0002
a Data listed as number (%) for frequency or mean  standard deviation for quantitative variables.
b p-value of the comparison between groups 3 and group 4.
c p-value of the comparison between group 3 and group 5.
d 64 subjects missing expiratory CT analysis.
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Table 5 Logistic regression for continuous oxygen use in hypoxemic and non-hypoxemic COPD patients.
Hypoxemic COPD Non-hypoxemic COPD
Continuous (n Z 61) vs.
Intermittent/no (n Z 21)
Continuous (n Z 132) vs.
Intermittent (n Z 122)
Continuous oxygen
user (n Z 132) vs.
Nonuser (n Z 717)
OR P OR P OR P
SpO2, % 0.86 0.30 1.09 0.19 0.88 0.04
Age, year 0.93 0.14 1.01 0.76 1.06 0.001
Gender, female 0.16 0.04 1.11 0.71 3.14 <0.0001
Race, White 0.86 0.88 0.44 0.05 0.28 0.0003
School completed,
high school or less
NA NA 1.75 0.06 NA NA
Enrolled Center, Denver 13.40 0.006 2.16 0.04 9.34 <0.0001
BMI, kg/m2 1.00 0.99 1.09 0.004 1.09 0.0003
Smoking status, current NA NA NA NA 0.38 0.009
FEV1, % predicted 1.02 0.45 0.97 0.004 0.91 <0.0001
CT emphysema, % total lung 0.98 0.59 1.02 0.14 1.04 0.001
MMRC dyspnea scale (3) 11.25 0.004 1.94 0.04 3.27 0.0001
NA: not assessed; in each model, the variables not significant in Tables 3 and 4 were not assessed.
Hypoxemia and oxygen therapy in COPDGene 1219hypoxemia in patients with moderate to very severe COPD;
however, emphysema was not significantly associated with
severe resting hypoxemia. In a real-world COPD population,
we found that a large number of COPD patients without
severe resting hypoxemia were using oxygen therapy, and
the use oxygen was affected by factors other than resting
oxygenation itself. Further studies, such as the NHLBI Long-
term Oxygen Therapy Trial, may be required to determine
the long-term effects of oxygen therapy in patients without
severe resting hypoxemia.Acknowledgments
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